



Herxheimer Support*

with CurcuWIN®

The Jarisch-Herxheimer reaction (“Herx”) is an immune reaction that occurs when bacterial surface proteins and other toxins are released into the bloodstream and tissues. Herx has been seen in individuals taking antibiotics. As bacteria die off, the release of dead and dying cells can trigger a surge of pro-inflammatory cytokines, chemokines, and enzymes. Excessive levels of these substances can aggravate sensitive tissues.

Herxheimer Support* (with CurcuWIN®) is a unique blend of herbal ingredients with added bicarbonates.* The ingredients were chosen for their ability to support systemwide health during Herxheimer reactions.*

Key Features

- Modulates intracellular pathways that control Herxheimer reactions*
- Superior bioavailability of curcuminoids
- Supports a healthy acid-base balance*



SKU #78260
60 vegetarian capsules

Herxheimer Support*

CurcuWIN® a water-soluble form of curcumin, the main bioactive constituent of *Curcuma longa* (turmeric).^{*} Owing to its immunomodulatory properties, *Curcuma longa* has a long history of use in Ayurvedic medicine.^{*} Curcumin modulates a number of different inflammatory pathways, including NF-κB, which plays a central role in Herxheimer reactions.^{*} In animal and human studies, supplemental curcumin has been shown to support normal functioning of inflammatory pathways in the heart, brain, lungs, joints, and blood vessels.^{*} In a well-controlled human clinical trial, the first curcumin study of its kind to compare commercial curcumin products, CurcuWIN® increased relative absorption of total curcuminoids 46-times over standard curcumin. CurcuWIN® also has longer-lasting action with higher serum concentrations after 12 hours.^{*}

Boswellia serrata comes from the Indian frankincense tree, which is native to India, North Africa, and the Middle East.^{*} Boswellia has long been used as an herbal remedy in Ayurvedic medicine.^{*} The tree resin contains phytochemicals known as boswellic acids, which support normal regulation of inflammatory pathways.^{*} In clinical studies, Boswellia has been shown to reduce C-reactive protein, as well as downregulate prostaglandin E2 and leukotrienes.^{*} Additionally, Boswellia inhibits matrix metalloproteinase.^{*}

Sodium bicarbonate / potassium bicarbonate supports the normal function of nearly all physiological processes that depends on the maintenance of an appropriate acid-base balance.^{*} A below-normal pH (acidosis) is a danger signal that triggers the release of pro-inflammatory cytokines.^{*} Bicarbonate, the second-most abundant anion in the human body, has long been used as a natural alkalizing agent.^{*} In animal models, oral bicarbonate has been shown to support optimal health in the heart, lungs, musculoskeletal system, and other organs.^{*}

References:

Aggarwal BB, Harikumar KB. *Int J Biochem Cell Biol.* 2009 Jan;41(1):40-59.
Ammon HP. *Adv Exp Med Biol.* 2016;928:291-327.
Baj T, Seth R. *Recent Pat Inflamm Allergy Drug Discov.* 2018 May 1;12(1):69-77.
Bengmark S. *JPEN J Parenter Enteral Nutr.* 2006 Jan-Feb;30(1):45-51.
Biolo G, et al. *Clin Nutr.* 2019;32(2):P652-9.
Biswas SK, et al. *Antioxid Redox Signal.* 2005 Jan 1;7(1-2):32-41.
Blain EJ, et al. *Phytother Res.* 2010 Jun;24(6):905-12.
Breuer A, et al. *Eur J Clin Microbiol Infect Dis.* 2021 May;40(5):1113-6.
Bryceson AD, et al. *Clin Sci.* 1972 Sep;43(3):343-54.
Bulut Y, et al. *J Immunol.* 2001;167:987-94.
Burge K, et al. *Int J Mol Sci.* 2019; 20(8):1912.
Butler T. *Am J Trop Med Hyg.* 2017 Jan 1;96(1):46.
Chin KY. *Drug Des Devel Ther.* 2016;10:3029.
Clarke JO, Mullin GE. *Nutr Clin Pract.* 2008 Feb;23(1):49-62.
Codolo G, et al. *Arthritis Rheum.* 2008 Nov;58(11):3609-17.
Davis LE, et al. *JAMA Neurol.* 2013 Aug 1;70(8):1060-4.
Dhakal A, Sbar E. *StatPearls Publishing;* 2021. PMID: 32491752.
Edey ME, et al. 2013. *J Biol Chem.* 2013;288:30485-94.
Erdile LF, Guy B. *Vaccine.* 1997 Jun 1;15(9):988-95.
Erra Diaz F, et al. *Mediators Inflamm.* 2018 Oct;2018.
Gong Z, et al. *Mol Nutr Food Res.* 2015 Nov;59(11):2132-42.
Hasanzadeh S, et al. *Pharmacol Res.* 2020 Sep 1;159:104921.
He J, et al. *Endocr Metab Immune Disord Drug Targets.* 2016;16(2):140-7.
He Y, et al. *Molecules.* 2015 May;20(5):9183-213.
Hewlings SJ, Kalman DS. *Foods.* 2017; 6(10): 92.
Horowitz RI, Freeman PR. *Int J Gen Med.* 2019;12:101.
Jancic CC, et al. 2011. *Cytokine.* 2011;57:258-68.
Jutras BL, et al. *Proc Natl Acad Sci U S A.* 2019 Jul 2;116(27):13498-507.
Juturu V, et al. *The FASEB Journal.* 2015 Apr;29:924-5.
Majeed M, et al. *Phytother Res.* 2019 May;33(5):1457-68.
Makuch S, et al. *Pharmaceuticals (Basel).* 2021 Apr;14(4):309.
Mannon EC, et al. *Pharmacol Res.* 2019 Mar 1;141:236-48.
Massip-Copiz MM, Santa-Coloma TA. *Eur J Cell Biol.* 2018;97:402-10.

Supplement Facts

Serving Size 2 Capsules
Servings Per Container 30

Amount Per Serving	% Daily Value**	
Sodium (as Sodium Bicarbonate)	68 mg	3%
Potassium (as Potassium Bicarbonate)	97 mg	2%
CurcuWIN® Turmeric (<i>Curcuma longa</i>) (Root) Extract (min. 20% Curcuminoids)	500 mg	†
Indian Frankincense Gum (<i>Boswellia serrata</i>) Extract (standardized to 65% Boswellic Acid)	250 mg	†

† Daily value not established.

**Percent Daily Value are based on a 2,000 calorie diet.

Other ingredients: Other ingredients: Hydroxypropyl methylcellulose, stearic acid, silicon dioxide.

Suggested Use: As a dietary supplement, 2 capsules daily with meals, or as directed by a healthcare practitioner.



CurcuWIN® is a registered trademark of OmniActive Health Technologies, Ltd.

Mito S, et al. *Biol Pharm Bull.* 2011 Jul 1;34(7):974-9.
Mogharrabi M, et al. *ARYA Atheroscler.* 2020 May;16(3):136.
Nau R, Eiffert H. *FEMS Immunol Med Microbiol.* 2005 Apr 1;44(1):1-6.
Negussie Y, et al. *J Exp Med.* 1992;175(5):1207-12.
Ng AW, et al. *Lung.* 2004;182:297-317.
Nyktyuk S, et al. *Reumatologia.* 2020;58(5):335.
Oliver JM, et al. *J Nutr Metab.* 2016;2016:1089653.
Praditya D, et al. *Front Microbiol.* 2019 May 3;10:912.
Pimenta D, Democratis J. *BMJ Case Rep.* 2013 Oct 9;2013:bcr2013201075.
Quade BN, et al. *Biochem Pharmacol.* 2020 Oct 9;114:278.
Rajamaki K, et al. 2013. *J Biol Chem.* 288:13410-9.
Ray SC, et al. *J Immunol.* 2018 May 15;200(10):3568-86.
Safayhi H, et al. *J Pharmacol Exp Therapeut.* 1992;261:143-6.
Sahabkar A, et al. *J Funct Foods.* 2015;18:898-909.
Sahin K, et al. *J Inflamm Res.* 2016;9:147.
Saja K, et al. *Int Immunopharmacol.* 2007 Dec 15;7(13):1659-67.
Santos-Parker JR, et al. *Aging (Albany NY).* 2017 Jan 3;9(1):187-208.
Shah VS, et al. *Science.* 2016;351:503-7.
Shakibaei M, et al. *Biochem Pharmacol.* 2007;73(9):1434-45.
Shin DH, et al. *Pflugers Arch.* 2020 Jul 4:1-6.
Soni KK, et al. *Curr Drug Discov Technol.* 2021 Jan 1;18(1):95-104.
Siddiqui MZ. *Indian J Pharm Sci.* 2011 May;73(3):255.
Siemoneit U, et al. *Br J Pharmacol.* 2011 Jan;162(1):147-62.
Sorrenti V, et al. *Front Pharmacol.* 2018 Mar 5:9:183.
Torres IM, et al. *Am J Physiol Lung Cell Mol Physiol.* 2017 Jul 1;313(1):L126-37.
Torres IM, et al. *Infect Immun.* 2014 Nov;82(11):4689-97.
Tracey KJ. *Nature.* 2002;420(6917):853-9.
Webster G, et al. *Pediatr Infect Dis J.* 2002;21(6):571-3.
White CM, et al. *Pharmacol Res.* 2019 Aug;146:104280.
Yarmohammadi F, et al. *Naunyn Schmiedebergs Arch Pharmacol.* 2021 Mar 5:1-3.
Yin H, et al. *J Immunol.* 2018 Apr 15;200(8):2835-46.
Yin T, et al. *PLoS One.* 2013 Aug 26;8(8):e72379.
Zhao Z, et al. *Mol Med Rep.* 2018; 17(4): 4953-8.